Ardelyx (ARDX) News Today $4.61 +0.04 (+0.88%) As of 02:58 PM Eastern Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 Time Period Ardelyx, Inc. (NASDAQ:ARDX) Shares Acquired by Vanguard Group Inc.Vanguard Group Inc. increased its position in shares of Ardelyx, Inc. (NASDAQ:ARDX - Free Report) by 5.6% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 14,362,659 shares of the biopharmacApril 13 at 3:40 AM | marketbeat.comArdelyx Sees Unusually Large Options Volume (NASDAQ:ARDX)Ardelyx, Inc. (NASDAQ:ARDX - Get Free Report) was the recipient of unusually large options trading on Wednesday. Traders bought 12,093 put options on the company. This represents an increase of approximately 411% compared to the typical volume of 2,365 put options.April 11, 2025 | marketbeat.comMichael Raab Sells 41,666 Shares of Ardelyx, Inc. (NASDAQ:ARDX) StockArdelyx, Inc. (NASDAQ:ARDX - Get Free Report) CEO Michael Raab sold 41,666 shares of Ardelyx stock in a transaction that occurred on Friday, April 4th. The shares were sold at an average price of $4.59, for a total transaction of $191,246.94. Following the completion of the transaction, the chief executive officer now directly owns 1,615,587 shares in the company, valued at $7,415,544.33. This trade represents a 2.51 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.April 10, 2025 | marketbeat.comPost-Hoc Analysis of the OPTIMIZE Study Supporting XPHOZAH® (tenapanor) to be Presented at the National Kidney Foundation Spring Clinical MeetingsApril 10, 2025 | globenewswire.comInvestors Buy High Volume of Ardelyx Put Options (NASDAQ:ARDX)April 10, 2025 | americanbankingnews.comArdelyx (NASDAQ:ARDX) Hits New 12-Month Low - Here's What HappenedArdelyx (NASDAQ:ARDX) Sets New 52-Week Low - Time to Sell?April 9, 2025 | marketbeat.comTrexquant Investment LP Acquires 702,487 Shares of Ardelyx, Inc. (NASDAQ:ARDX)Trexquant Investment LP lifted its holdings in shares of Ardelyx, Inc. (NASDAQ:ARDX - Free Report) by 344.7% during the 4th quarter, according to the company in its most recent filing with the SEC. The fund owned 906,311 shares of the biopharmaceutical company's stock after purchasing an additionalApril 7, 2025 | marketbeat.comRaymond James Financial Inc. Acquires Shares of 183,490 Ardelyx, Inc. (NASDAQ:ARDX)Raymond James Financial Inc. bought a new position in shares of Ardelyx, Inc. (NASDAQ:ARDX - Free Report) during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm bought 183,490 shares of the biopharmaceutical company's stock, vaApril 6, 2025 | marketbeat.comCommit To Purchase Ardelyx At $4, Earn 20.5% Annualized Using OptionsApril 2, 2025 | nasdaq.comKnott David M Jr Reduces Holdings in Ardelyx, Inc. (NASDAQ:ARDX)Knott David M Jr reduced its position in Ardelyx, Inc. (NASDAQ:ARDX - Free Report) by 10.3% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 612,270 shares of the biopharmaceutical company's stock after selliApril 2, 2025 | marketbeat.comArdelyx to Share a Post-Hoc Analysis of the OPTIMIZE Study Supporting XPHOZAH® (tenapanor) at the National Kidney Foundation Spring Clinical MeetingsMarch 31, 2025 | globenewswire.comArdelyx (NASDAQ:ARDX) Trading Down 3.5% - Time to Sell?Ardelyx (NASDAQ:ARDX) Stock Price Down 3.5% - What's Next?March 26, 2025 | marketbeat.comArdelyx, Inc. (NASDAQ:ARDX) Stock Position Lifted by Charles Schwab Investment Management Inc.Charles Schwab Investment Management Inc. lifted its holdings in Ardelyx, Inc. (NASDAQ:ARDX - Free Report) by 5.0% in the 4th quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 2,035,135 shares of the biopharmaceutical company's stock aftMarch 23, 2025 | marketbeat.comArdelyx, Inc. (NASDAQ:ARDX) Receives Average Rating of "Buy" from BrokeragesArdelyx, Inc. (NASDAQ:ARDX - Get Free Report) has been assigned an average rating of "Buy" from the twelve research firms that are presently covering the company, Marketbeat Ratings reports. Two research analysts have rated the stock with a hold recommendation, eight have assigned a buy recommendaMarch 22, 2025 | marketbeat.com2 Small-Cap Stocks Set to Skyrocket With Upside Potential Between 36% and 102%March 21, 2025 | msn.comArdelyx (NASDAQ:ARDX) Shares Down 2.9% - Should You Sell?Ardelyx (NASDAQ:ARDX) Stock Price Down 2.9% - What's Next?March 20, 2025 | marketbeat.comArdelyx (NASDAQ:ARDX) Upgraded by Piper Sandler to "Hold" RatingPiper Sandler raised Ardelyx to a "hold" rating in a report on Wednesday.March 15, 2025 | marketbeat.comArdelyx Announces the First Recipients of Derek Forfang Patient Advocate AwardMarch 13, 2025 | globenewswire.comPiper Sandler Sticks to Their Hold Rating for Ardelyx (ARDX)March 13, 2025 | markets.businessinsider.comMichael Raab Sells 41,668 Shares of Ardelyx, Inc. (NASDAQ:ARDX) StockArdelyx, Inc. (NASDAQ:ARDX - Get Free Report) CEO Michael Raab sold 41,668 shares of the business's stock in a transaction on Friday, March 7th. The stock was sold at an average price of $5.36, for a total transaction of $223,340.48. Following the sale, the chief executive officer now owns 1,635,138 shares in the company, valued at $8,764,339.68. The trade was a 2.48 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink.March 8, 2025 | marketbeat.comArdelyx (NASDAQ:ARDX) Coverage Initiated at ScotiabankScotiabank began coverage on Ardelyx in a report on Friday. They set a "sector outperform" rating and a $15.00 price target for the company.March 8, 2025 | marketbeat.comScotiabank Initiates Coverage of Ardelyx (ARDX) with Sector Outperform RecommendationMarch 8, 2025 | msn.comArdelyx (NASDAQ:ARDX) Earns "Buy" Rating from LADENBURG THALM/SH SHLADENBURG THALM/SH SH reaffirmed a "buy" rating and set a $11.00 price target on shares of Ardelyx in a research report on Friday.March 8, 2025 | marketbeat.comArdelyx, Inc. (NASDAQ:ARDX) CEO Sells $223,340.48 in StockMarch 8, 2025 | insidertrades.comArdelyx initiated with an Outperform at ScotiabankMarch 7, 2025 | markets.businessinsider.comArdelyx price target lowered to $11 from $13.50 at LadenburgMarch 7, 2025 | markets.businessinsider.comCantor Fitzgerald Comments on Ardelyx FY2025 EarningsArdelyx, Inc. (NASDAQ:ARDX - Free Report) - Stock analysts at Cantor Fitzgerald issued their FY2025 earnings estimates for Ardelyx in a research report issued on Tuesday, March 4th. Cantor Fitzgerald analyst P. Agrawal forecasts that the biopharmaceutical company will post earnings per share of (March 7, 2025 | marketbeat.comArdelyx (NASDAQ:ARDX) Rating Increased to Strong-Buy at Cantor FitzgeraldCantor Fitzgerald upgraded Ardelyx to a "strong-buy" rating in a research note on Tuesday.March 6, 2025 | marketbeat.comArdelyx initiated with a Buy at BTIGMarch 4, 2025 | markets.businessinsider.comBTIG initiates Ardelyx with a Buy, sees attractive entry point after pullbackMarch 4, 2025 | markets.businessinsider.comArdelyx (NASDAQ:ARDX) Now Covered by Analysts at BTIG ResearchBTIG Research began coverage on shares of Ardelyx in a research report on Tuesday. They set a "buy" rating and a $14.00 price objective on the stock.March 4, 2025 | marketbeat.comJones Financial Companies Lllp Grows Stake in Ardelyx, Inc. (NASDAQ:ARDX)Jones Financial Companies Lllp increased its holdings in shares of Ardelyx, Inc. (NASDAQ:ARDX - Free Report) by 67.2% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 1,452,176 shares of the biopharmaceuticMarch 4, 2025 | marketbeat.comArdelyx (NASDAQ:ARDX) Stock Price Up 5.3% on Insider Buying ActivityArdelyx (NASDAQ:ARDX) Trading Up 5.3% on Insider Buying ActivityFebruary 28, 2025 | marketbeat.comLos Angeles Capital Management LLC Purchases 299,275 Shares of Ardelyx, Inc. (NASDAQ:ARDX)Los Angeles Capital Management LLC grew its holdings in Ardelyx, Inc. (NASDAQ:ARDX - Free Report) by 175.5% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 469,819 shares of the biopharmaceutical companFebruary 28, 2025 | marketbeat.comArdelyx, Inc. (NASDAQ:ARDX) Director Acquires $388,645.00 in StockArdelyx, Inc. (NASDAQ:ARDX - Get Free Report) Director David M. Mott acquired 77,729 shares of Ardelyx stock in a transaction dated Monday, February 24th. The stock was purchased at an average price of $5.00 per share, for a total transaction of $388,645.00. Following the completion of the acquisition, the director now directly owns 2,015,494 shares in the company, valued at approximately $10,077,470. This represents a 4.01 % increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through this link.February 27, 2025 | marketbeat.comInsider Buying: Ardelyx, Inc. (NASDAQ:ARDX) Director Buys 77,729 Shares of StockFebruary 27, 2025 | insidertrades.comArdelyx Full Year 2024 Earnings: Revenues Beat Expectations, EPS LagsFebruary 26, 2025 | finance.yahoo.comArdelyx, Inc.: Tenapanor Approved in China for HyperphosphatemiaFebruary 26, 2025 | finanznachrichten.deArdelyx announces approval of NDA by China for tenapanorFebruary 26, 2025 | markets.businessinsider.comTenapanor Approved in China for HyperphosphatemiaFebruary 26, 2025 | globenewswire.comInstitutional investors may adopt severe steps after Ardelyx, Inc.'s (NASDAQ:ARDX) latest 11% drop adds to a year lossesFebruary 26, 2025 | finance.yahoo.comArdelyx to Participate in Upcoming Investor ConferencesFebruary 25, 2025 | globenewswire.comArdelyx, Inc. (NASDAQ:ARDX) Receives Consensus Recommendation of "Buy" from AnalystsShares of Ardelyx, Inc. (NASDAQ:ARDX - Get Free Report) have been assigned an average recommendation of "Buy" from the nine research firms that are currently covering the stock, MarketBeat.com reports. Two equities research analysts have rated the stock with a hold recommendation, five have issuedFebruary 25, 2025 | marketbeat.comArdelyx: Limited Pipeline, Rising Costs, And Uncertain Growth Ahead (Downgrade)February 24, 2025 | seekingalpha.comFY2029 Earnings Estimate for Ardelyx Issued By HC WainwrightArdelyx, Inc. (NASDAQ:ARDX - Free Report) - HC Wainwright issued their FY2029 EPS estimates for Ardelyx in a research note issued to investors on Friday, February 21st. HC Wainwright analyst E. Arce forecasts that the biopharmaceutical company will post earnings per share of $1.18 for the year. HFebruary 24, 2025 | marketbeat.comFY2029 Earnings Estimate for Ardelyx Issued By WedbushArdelyx, Inc. (NASDAQ:ARDX - Free Report) - Wedbush reduced their FY2029 EPS estimates for Ardelyx in a note issued to investors on Friday, February 21st. Wedbush analyst L. Chico now anticipates that the biopharmaceutical company will post earnings of $0.88 per share for the year, down from theiFebruary 24, 2025 | marketbeat.comQ3 Earnings Estimate for Ardelyx Issued By Leerink PartnrsArdelyx, Inc. (NASDAQ:ARDX - Free Report) - Investment analysts at Leerink Partnrs issued their Q3 2025 earnings estimates for Ardelyx in a research note issued to investors on Thursday, February 20th. Leerink Partnrs analyst R. Ruiz expects that the biopharmaceutical company will post earnings oFebruary 24, 2025 | marketbeat.comArdelyx, Inc. (NASDAQ:ARDX) Insider Laura A. Williams Sells 4,941 SharesArdelyx, Inc. (NASDAQ:ARDX - Get Free Report) insider Laura A. Williams sold 4,941 shares of the company's stock in a transaction on Thursday, February 20th. The stock was sold at an average price of $5.62, for a total value of $27,768.42. Following the sale, the insider now directly owns 303,804 shares in the company, valued at $1,707,378.48. This represents a 1.60 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink.February 22, 2025 | marketbeat.comJustin A. Renz Sells 5,171 Shares of Ardelyx, Inc. (NASDAQ:ARDX) StockArdelyx, Inc. (NASDAQ:ARDX - Get Free Report) CFO Justin A. Renz sold 5,171 shares of the company's stock in a transaction that occurred on Thursday, February 20th. The stock was sold at an average price of $5.62, for a total value of $29,061.02. Following the transaction, the chief financial officer now directly owns 285,968 shares in the company, valued at $1,607,140.16. The trade was a 1.78 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website.February 22, 2025 | marketbeat.comMichael Raab Sells 22,964 Shares of Ardelyx, Inc. (NASDAQ:ARDX) StockArdelyx, Inc. (NASDAQ:ARDX - Get Free Report) CEO Michael Raab sold 22,964 shares of the stock in a transaction that occurred on Thursday, February 20th. The shares were sold at an average price of $5.62, for a total transaction of $129,057.68. Following the completion of the transaction, the chief executive officer now directly owns 1,085,755 shares of the company's stock, valued at approximately $6,101,943.10. The trade was a 2.07 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.February 22, 2025 | marketbeat.com Remove Ads Get Ardelyx News Delivered to You Automatically Sign up to receive the latest news and ratings for ARDX and its competitors with MarketBeat's FREE daily newsletter. Email Address ARDX Media Mentions By Week ARDX Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ARDX News Sentiment▼0.540.80▲Average Medical News Sentiment ARDX News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ARDX Articles This Week▼99▲ARDX Articles Average Week Remove Ads Get Ardelyx News Delivered to You Automatically Sign up to receive the latest news and ratings for ARDX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies ELAN News Today PCVX News Today RYTM News Today PTCT News Today ZLAB News Today ACLX News Today RARE News Today RNA News Today AKRO News Today MRUS News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:ARDX) was last updated on 4/15/2025 by MarketBeat.com Staff From Our PartnersElon Set to Shock the World by May 1st ?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | Sponsored[Action Required] Claim Your FREE IRS Loophole GuideThis shouldn't surprise anyone who's been paying attention, but... Pres. Trump may be about to unleash the ...Colonial Metals | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredElon’s Silver Play? Trump Clears the PathNothing is confirmed—yet. But Musk has disrupted every industry he's touched, and Trump's policies make the ti...Priority Gold | SponsoredGet Your Bank Account “Fed Invasion” Ready with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredElon Musk Confirms: Tesla’s Optimus is Replacing Workers… and Heading to MarsElon Musk just confirmed Tesla’s robot will go to Mars. But on Earth, it may trigger a trillion-dollar tech sh...InvestorPlace | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredTrump Orders 'National Digital Asset Stockpile'‘Digital Asset Reserve’ for THIS Coin??? Get all the details before this story gains even more tractionCrypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Ardelyx, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Ardelyx With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy ARDX Stock Free ARDX Stock Alerts